You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 135 No. 12, December 1975 TABLE OF CONTENTS
  Archives
  •  Online Features
  CLINICAL NOTES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (5)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Toxicity Secondary to Intravenously Administered Chloroform in Humans

Richard M. Timms, MD; Kenneth M. Moser, MD

Arch Intern Med. 1975;135(12):1601-1603.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The association of pulmonary disease and chloroform (CHCL3) injection has not been recorded previously in humans as far as we know. However, other halogenated, volatile hydrocarbons such as carbon tetrachloride and trichlorethane are known to induce pulmonary injury. Carbon tetrachloride (CHCL4) causes pulmonary edema and hemorrhage when given intravenously to dogs.1 Oral doses of carbon tetrachloride were recently shown to cause diffuse pulmonary damage in rats at sublethal dosage levels.2 There is evidence that inhaling high concentrations of trichloroethane (CH3CCL3) may cause pulmonary disease.3,4

In 1973, the Federal Food and Drug Administration concluded that trichloroethane may be responsible for side-effects from over-the-counter aerosols, and they asked that manufacturers of aerosols containing trichloroethane recall their products.5 Most patients who have ingested toxic doses of chloroform or trichloroethane have apparently not developed secondary pulmonary disease. The clinical course of a patient who developed pulmonary infiltrates and acute respiratory distress after injecting chloroform . . . [Full Text PDF of this Article]


Author Affiliations

From the Pulmonary Division, Department of Medicine, University of California, San Diego.


Footnotes

Received for publication Dec 30,1974; accepted Feb 26, 1975.

Reprint requests to 225 W Dickinson St, San Diego, CA 92103 (Dr. Timms).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1975 American Medical Association. All Rights Reserved.